Latest Press Releases from Claris Bio.

Crystalys Therapeutics has secured $130 million in series B funding to advance its gout drug dotinurad through phase 3 trials and prepare for commercial launch. Frazier Life Sciences led the round, with participation from Wellington Management, HBM Healthcare Investments, and existing backers including Novo Holdings. The financing comes less than a year after Crystalys raised $205 million in series A. The funds will support two ongoing registration-directed phase 3 trials and a phase 2 study, extending the company's runway through multiple clinical milestones. Dotinurad is a once-daily oral URAT1 inhibitor that helps kidneys excrete uric acid. The drug is already approved in Japan, China, the Philippines, Taiwan and Thailand. Crystalys acquired rights to dotinurad from Urica Therapeutics in July 2024 for 35% equity and a 3% royalty on future sales.

Ray Therapeutics, a US clinical-stage biotech company co-founded by optogenetics pioneer Zhuo-Hua Pan and Robinhood CEO Vlad Tenev, has raised $125 million in an oversubscribed Series C round led by Janus Henderson Investors. Adage Capital Management, Franklin Templeton, Invus and Marshall Wace participated, with existing investors including 4BIO Capital and Novo Holdings also contributing. The company is developing optogenetic therapies for degenerative retinal diseases. Its lead candidate, RTx-015, targets retinitis pigmentosa and has received RMAT designation from the FDA and PRIME designation from the EMA. A second programme, RTx-021, focuses on macular diseases including Stargardt disease. The funding will advance RTx-015 through late-stage clinical trials and accelerate RTx-021's development. Ray's technology uses modified light-sensitive proteins to restore vision by reprogramming surviving retinal neurons.